Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Pemetrexed vs Observation in Recurrent or Metastatic Urothelial Carcinoma After Platinum Chemotherapy
KCT0004751Phase 3Recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pemetrexed in transitional cell carcinoma of the bladder (TCC), ureteral urothelial carcinoma, urethral urothelial carcinoma, Renal pelvis urothelial carcinoma (UTUC), transitional cell carcinoma (TCC), sponsored by Samyang Biopharmaceuticals Corporation. Started Oct 2016; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
transitional cell carcinoma of the bladder (TCC)ureteral urothelial carcinomaurethral urothelial carcinomaRenal pelvis urothelial carcinoma (UTUC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on KCT0004751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004751.